投资要点事件:公司4月底发布2024年年报,公司2024年实现收入272.1亿元,同比+56.2%。归母净利润-49.8亿元,进一步减亏,全年实现非GAAP经营性利润为正。得益于泽布替尼全球销售的快速增长,业绩略 超市 场预期。公司2025年全年收入指引为49亿至53亿美金,GAAP经营性利润转正。泽布替尼全球销售快速增长,BCL2抑制剂和BTK CDAC巩固血液瘤领军地位。泽布替尼2024年全球...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.